Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

RIP off STAT3 to counteract tumor progression

Jawahar Kopparam¹, Etienne Meylan¹

¹a Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne , Lausanne , Switzerland.

Cell Cycle (Georgetown, Tex.)

|August 19, 2017

Summary

No abstract available in PubMed .

Keywords:

RIP4 STAT3 lung adenocarcinoma mouse models of cancer oncogenic Kras tumor dedifferentiation

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Bcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma.

EMBO molecular medicine·2026

Same author

PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibition.

Communications biology·2026

Same author

Low-dose photodynamic therapy promotes vascular E-selectin expression in chest malignancies, improving immune infiltration and tumor control.

Journal for immunotherapy of cancer·2025

Same author

Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7<sup>th</sup> immunorad conference.

Oncoimmunology·2024

Same author

Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition.

Cancer immunology research·2024

Same author

Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma.

British journal of cancer·2024